List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3010967/publications.pdf Version: 2024-02-01



ΟΛΥΙΟΙΝΙΙΤΤ

#	Article	IF	CITATIONS
1	Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends in Pharmacological Sciences, 2006, 27, 402-409.	8.7	1,237
2	Drug harms in the UK: a multicriteria decision analysis. Lancet, The, 2010, 376, 1558-1565.	13.7	1,201
3	Development of a rational scale to assess the harm of drugs of potential misuse. Lancet, The, 2007, 369, 1047-1053.	13.7	1,040
4	Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry,the, 2016, 3, 619-627.	7.4	988
5	Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2138-2143.	7.1	789
6	The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience, 2014, 8, 20.	2.0	673
7	Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 2021, 384, 1402-1411.	27.0	643
8	Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4853-4858.	7.1	586
9	Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2005, 19, 567-596.	4.0	537
10	Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology, 2018, 235, 399-408.	3.1	537
11	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 2015, 29, 459-525.	4.0	528
12	The dopamine theory of addiction: 40 years of highs and lows. Nature Reviews Neuroscience, 2015, 16, 305-312.	10.2	517
13	Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2014, 28, 403-439.	4.0	511
14	British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. Journal of Psychopharmacology, 2010, 24, 1577-1601.	4.0	484
15	Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Frontiers in Pharmacology, 2017, 8, 974.	3.5	454
16	Serotonin and brain function: a tale of two receptors. Journal of Psychopharmacology, 2017, 31, 1091-1120.	4.0	440
17	Amphetamine, past and present $\hat{a} \in \hat{a}$ a pharmacological and clinical perspective. Journal of Psychopharmacology, 2013, 27, 479-496.	4.0	431
18	Role of GABA in anxiety and depression. Depression and Anxiety, 2007, 24, 495-517.	4.1	416

#	Article	IF	CITATIONS
19	Homological scaffolds of brain functional networks. Journal of the Royal Society Interface, 2014, 11, 20140873.	3.4	415
20	Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. Current Biology, 2016, 26, 1043-1050.	3.9	371
21	Broadband Cortical Desynchronization Underlies the Human Psychedelic State. Journal of Neuroscience, 2013, 33, 15171-15183.	3.6	364
22	GABA system dysfunction in autism and related disorders: From synapse to symptoms. Neuroscience and Biobehavioral Reviews, 2012, 36, 2044-2055.	6.1	346
23	Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports, 2017, 7, 13187.	3.3	346
24	Decreased Brain GABAA-Benzodiazepine Receptor Binding in Panic Disorder. Archives of General Psychiatry, 1998, 55, 715.	12.3	344
25	Estimating the Harms of Nicotine-Containing Products Using the MCDA Approach. European Addiction Research, 2014, 20, 218-225.	2.4	337
26	The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. Journal of Psychopharmacology, 2007, 21, 461-471.	4.0	311
27	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nature Genetics, 2015, 47, 717-726.	21.4	310
28	Patients' Accounts of Increased "Connectedness―and "Acceptance―After Psilocybin for Treatment-Resistant Depression. Journal of Humanistic Psychology, 2017, 57, 520-564.	2.1	309
29	Enhanced repertoire of brain dynamical states during the psychedelic experience. Human Brain Mapping, 2014, 35, 5442-5456.	3.6	298
30	Resolution of Sleepiness and Fatigue in Major Depressive Disorder: A Comparison of Bupropion and the Selective Serotonin Reuptake Inhibitors. Biological Psychiatry, 2006, 60, 1350-1355.	1.3	296
31	New insights into the role of the GABAA–benzodiazepine receptor in psychiatric disorder. British Journal of Psychiatry, 2001, 179, 390-396.	2.8	295
32	Unusual interactions of benzodiazepine receptor antagonists. Nature, 1982, 295, 436-438.	27.8	292
33	BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. Journal of Psychopharmacology, 2012, 26, 899-952.	4.0	268
34	The anxiogenic action of benzodiazepine antagonists. Neuropharmacology, 1982, 21, 1033-1037.	4.1	266
35	Flumazenil Provocation of Panic Attacks. Archives of General Psychiatry, 1990, 47, 917.	12.3	261
36	Tryptophan depletion and its implications for psychiatry. British Journal of Psychiatry, 2001, 178, 399-405.	2.8	246

#	Article	IF	CITATIONS
37	LSDâ€induced entropic brain activity predicts subsequent personality change. Human Brain Mapping, 2016, 37, 3203-3213.	3.6	240
38	Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Reviews Neuroscience, 2013, 14, 577-585.	10.2	239
39	`Seeing through a glass darkly': casting light on imidazoline `I' sites. Trends in Pharmacological Sciences, 1998, 19, 381-390.	8.7	238
40	Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2014, 28, 179-203.	4.0	233
41	Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2007, 21, 10-41.	4.0	232
42	Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Frontiers in Human Neuroscience, 2016, 10, 269.	2.0	231
43	Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World Journal of Biological Psychiatry, 2017, 18, 162-214.	2.6	226
44	Predicting Responses to Psychedelics: A Prospective Study. Frontiers in Pharmacology, 2018, 9, 897.	3.5	226
45	A web-based survey on mephedrone. Drug and Alcohol Dependence, 2011, 118, 19-22.	3.2	225
46	The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychological Medicine, 2016, 46, 1379-1390.	4.5	222
47	Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology, 2018, 142, 200-218.	4.1	222
48	Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis. Schizophrenia Bulletin, 2013, 39, 1343-1351.	4.3	211
49	LSD enhances suggestibility in healthy volunteers. Psychopharmacology, 2015, 232, 785-794.	3.1	207
50	Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Human Brain Mapping, 2015, 36, 3137-3153.	3.6	196
51	Defining Substance Use Disorders: Do We Really Need More Than Heavy Use?. Alcohol and Alcoholism, 2013, 48, 633-640.	1.6	193
52	The neuropharmacology of serotonin and noradrenaline in depression. International Clinical Psychopharmacology, 2002, 17, S1-S12.	1.7	185
53	The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Frontiers in Human Neuroscience, 2014, 8, 204.	2.0	181
54	Benzodiazepines: Risks and benefits. A reconsideration. Journal of Psychopharmacology, 2013, 27, 967-971.	4.0	177

#	Article	IF	CITATIONS
55	Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. Journal of Psychopharmacology, 2015, 29, 596-607.	4.0	175
56	Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine, 2022, 28, 844-851.	30.7	175
57	Striatal dopamine D2/D3 receptor binding in pathological gambling is correlated with mood-related impulsivity. NeuroImage, 2012, 63, 40-46.	4.2	173
58	British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. Journal of Psychopharmacology, 2019, 33, 923-947.	4.0	173
59	Human Taste Thresholds Are Modulated by Serotonin and Noradrenaline. Journal of Neuroscience, 2006, 26, 12664-12671.	3.6	171
60	Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. British Journal of Psychiatry, 2012, 200, 238-244.	2.8	170
61	Serotonin 5-HT <sub>1A</sub> receptor binding in people with panic disorder: positron emission tomography study. British Journal of Psychiatry, 2008, 193, 229-234.	2.8	166
62	The size, burden and cost of disorders of the brain in the UK. Journal of Psychopharmacology, 2013, 27, 761-770.	4.0	163
63	Psychedelic Psychiatry's Brave New World. Cell, 2020, 181, 24-28.	28.9	162
64	Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2004, 18, 293-335.	4.0	160
65	Antidepressant-induced jitteriness/anxiety syndrome: systematic review. British Journal of Psychiatry, 2009, 194, 483-490.	2.8	160
66	Overview of Diagnosis and Drug Treatments of Anxiety Disorders. CNS Spectrums, 2005, 10, 49-56.	1.2	159
67	Invited review: the evolution of antidepressant mechanisms. Fundamental and Clinical Pharmacology, 2004, 18, 1-21.	1.9	158
68	Effects of psilocybin therapy on personality structure. Acta Psychiatrica Scandinavica, 2018, 138, 368-378.	4.5	156
69	European rating of drug harms. Journal of Psychopharmacology, 2015, 29, 655-660.	4.0	153
70	Panic Attacks. British Journal of Psychiatry, 1992, 160, 165-178.	2.8	152
71	Stratified medicine for mental disorders. European Neuropsychopharmacology, 2014, 24, 5-50.	0.7	152
72	Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin. NeuroImage, 2019, 199, 127-142.	4.2	152

#	Article	IF	CITATIONS
73	Changes in Regional Cerebral Blood Flow Elicited by Craving Memories in Abstinent Opiate-Dependent Subjects. American Journal of Psychiatry, 2001, 158, 1680-1686.	7.2	151
74	Noradrenaline and attention lapses. Nature, 1996, 380, 291-291.	27.8	149
75	The effects of elevated endogenous GABA levels on movement-related network oscillations. NeuroImage, 2013, 66, 36-41.	4.2	148
76	Altered Central α2-Adrenoceptor Sensitivity in Panic Disorder. Archives of General Psychiatry, 1989, 46, 165.	12.3	147
77	Neural correlates of the DMT experience assessed with multivariate EEG. Scientific Reports, 2019, 9, 16324.	3.3	144
78	Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis â€~amotivational' hypotheses. Psychopharmacology, 2016, 233, 3537-3552.	3.1	139
79	5â€HT radioligands for human brain imaging with PET and SPECT. Medicinal Research Reviews, 2013, 33, 54-111.	10.5	138
80	Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology, 2007, 22, 323-329.	1.7	137
81	Therapeutic effects of classic serotonergic psychedelics: A systematic review of modernâ€era clinical studies. Acta Psychiatrica Scandinavica, 2021, 143, 101-118.	4.5	137
82	The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity. Biological Psychiatry, 2015, 78, 554-562.	1.3	136
83	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. European Neuropsychopharmacology, 2015, 25, 2318-2325.	0.7	135
84	Searching for perfect sleep: the continuing evolution of GABA <sub>A</sub> receptor modulators as hypnotics. Journal of Psychopharmacology, 2010, 24, 1601-1612.	4.0	134
85	Neural substrates of cue reactivity and craving in gambling disorder. Translational Psychiatry, 2017, 7, e992-e992.	4.8	134
86	Measuring Endogenous 5-HT Release by Emission Tomography: Promises and Pitfalls. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 1682-1706.	4.3	132
87	The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology, 2018, 235, 505-519.	3.1	131
88	Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology, 2018, 142, 263-269.	4.1	126
89	Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse. Pharmacological Reviews, 2015, 67, 872-1004.	16.0	125
90	DMT Models the Near-Death Experience. Frontiers in Psychology, 2018, 9, 1424.	2.1	122

#	Article	IF	CITATIONS
91	Functional Studies of Specific Imidazoline-2 Receptor Ligands. Annals of the New York Academy of Sciences, 1995, 763, 125-139.	3.8	121
92	Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. Journal of Psychopharmacology, 2019, 33, 1039-1057.	4.0	121
93	β-carboline binding to imidazoline receptors. Drug and Alcohol Dependence, 2001, 64, 203-208.	3.2	118
94	Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics. World Journal of Biological Psychiatry, 2016, 17, 321-365.	2.6	118
95	Determination of [ <sup>11</sup> C]PBR28 Binding Potential <i>in vivo:</i> A First Human TSPO Blocking Study. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 989-994.	4.3	117
96	Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers. Depression and Anxiety, 2005, 21, 18-25.	4.1	116
97	The Current Status of Psychedelics in Psychiatry. JAMA Psychiatry, 2021, 78, 121.	11.0	116
98	Characterization and autoradiographical localization of nonâ€edrenoceptor idazoxan binding sites in the rat brain. British Journal of Pharmacology, 1992, 106, 1019-1027.	5.4	115
99	LSD enhances the emotional response to music. Psychopharmacology, 2015, 232, 3607-3614.	3.1	115
100	Acute Tryptophan Depletion. Part I: Rationale and Methodology. Australian and New Zealand Journal of Psychiatry, 2005, 39, 558-564.	2.3	114
101	Imaging the GABA-Benzodiazepine Receptor Subtype Containing the α5-Subunit In Vivo with [11C]Ro15 4513 Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 878-889.	4.3	113
102	Gene Expression Subtypes in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. Journal of Infectious Diseases, 2008, 197, 1171-1184.	4.0	113
103	Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. Journal of Psychopharmacology, 2016, 30, 344-353.	4.0	113
104	Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Current Opinion in Pharmacology, 2005, 5, 87-93.	3.5	106
105	Addiction: brain mechanisms and their treatment implications. Lancet, The, 1996, 347, 31-36.	13.7	104
106	Endogenous Opioid Release in the Human Brain Reward System Induced by Acute Amphetamine Administration. Biological Psychiatry, 2012, 72, 371-377.	1.3	104
107	The psychobiology of anxiolytic drugs. , 2000, 88, 213-227.		103
108	Blockade of alcohol's amnestic activity in humans by an α5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology, 2007, 53, 810-820.	4.1	103

#	Article	IF	CITATIONS
109	Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology, 2022, 36, 258-272.	4.0	103
110	Generalized anxiety disorder: comorbidity, comparative biology and treatment. International Journal of Neuropsychopharmacology, 2002, 5, 315-325.	2.1	102
111	Gamma hydroxy butyrate abuse and dependency. Journal of Psychopharmacology, 2005, 19, 195-204.	4.0	102
112	Innovative solutions to novel drug development in mental health. Neuroscience and Biobehavioral Reviews, 2013, 37, 2438-2444.	6.1	102
113	Acute Carbon Dioxide Exposure in Healthy Adults: Evaluation of a Novel Means of Investigating the Stress Response. Journal of Neuroendocrinology, 2004, 16, 256-264.	2.6	101
114	CABA <sub>A</sub> Receptors: Subtypes, Regional Distribution, and Function. Journal of Clinical Sleep Medicine, 2006, 02, .	2.6	100
115	GABAB Receptors in Addiction and Its Treatment. Advances in Pharmacology, 2010, 58, 373-396.	2.0	99
116	Anhedonia revisited: Is there a role for dopamine-targeting drugs for depression?. Journal of Psychopharmacology, 2013, 27, 869-877.	4.0	98
117	Alcohol and the brain. British Journal of Psychiatry, 1999, 175, 114-119.	2.8	97
118	The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: A pilot [11C]Ro15-4513 positron emission tomography study. Neuropharmacology, 2013, 68, 195-201.	4.1	97
119	Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers. Neuropsychopharmacology, 2016, 41, 1742-1750.	5.4	96
120	Role of GABA in memory and anxiety. , 1996, 4, 100-110.		95
121	LSD modulates music-induced imagery via changes in parahippocampal connectivity. European Neuropsychopharmacology, 2016, 26, 1099-1109.	0.7	95
122	Serotonin and panic. British Journal of Psychiatry, 1998, 172, 465-471.	2.8	94
123	Self-blinding citizen science to explore psychedelic microdosing. ELife, 2021, 10, .	6.0	94
124	Acute Tryptophan Depletion. Part II: Clinical Effects and Implications. Australian and New Zealand Journal of Psychiatry, 2005, 39, 565-574.	2.3	93
125	Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. Journal of Psychopharmacology, 2008, 22, 3-6.	4.0	93
126	Inhalation of 35% CO2 results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology, 2002, 27, 715-729.	2.7	92

#	Article	IF	CITATIONS
127	IS THERE COGNITIVE IMPAIRMENT IN CLINICALLY â€~HEALTHY' ABSTINENT ALCOHOL DEPENDENCE?. Alcohol and Alcoholism, 2005, 40, 498-503.	1.6	92
128	Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. Journal of Psychopharmacology, 2020, 34, 167-180.	4.0	92
129	The Australian drug harms ranking study. Journal of Psychopharmacology, 2019, 33, 759-768.	4.0	91
130	Neurobiology of addiction and implications for treatment. British Journal of Psychiatry, 2003, 182, 97-100.	2.8	90
131	The blind men and the elephant: Systematic review of systematic reviews of cannabis use related health harms. European Neuropsychopharmacology, 2020, 33, 1-35.	0.7	90
132	Vienna Declaration: a call for evidence-based drug policies. Lancet, The, 2010, 376, 310-312.	13.7	89
133	Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. Journal of Psychopharmacology, 2002, 16, 5-14.	4.0	87
134	The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse, 2007, 61, 637-645.	1.2	87
135	Equasy — An overlooked addiction with implications for the current debate on drug harms. Journal of Psychopharmacology, 2009, 23, 3-5.	4.0	87
136	The psychobiology of anxiolytic drugs. , 2000, 88, 197-212.		85
137	Opioids and anxiety. Journal of Psychopharmacology, 2011, 25, 1415-1433.	4.0	85
138	Amphetamine induced endogenous opioid release in the human brain detected with [11C]carfentanil PET: replication in an independent cohort. International Journal of Neuropsychopharmacology, 2014, 17, 2069-2074.	2.1	85
139	Overexcitement and Disinhibition. British Journal of Psychiatry, 1990, 157, 491-499.	2.8	84
140	Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biological Psychiatry, 2004, 56, 503-509.	1.3	84
141	ABSTINENCE SYMPTOMS AFTER WITHDRAWAL OF TRANQUILLISING DRUGS: IS THERE A COMMON NEUROCHEMICAL MECHANISM?. Lancet, The, 1982, 320, 360-362.	13.7	83
142	Pharmacology of saccadic eye movements in man. Psychopharmacology, 1991, 105, 361-367.	3.1	83
143	A proposal for an updated neuropsychopharmacological nomenclature. European Neuropsychopharmacology, 2014, 24, 1005-1014.	0.7	83
144	Characterisation and localisation of []2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I2 receptors. European Journal of Pharmacology, 1998, 353, 123-135.	3.5	82

#	Article	IF	CITATIONS
145	Mourning and melancholia revisited: correspondences between principles of Freudian metapsychology and empirical findings in neuropsychiatry. Annals of General Psychiatry, 2008, 7, 9.	2.7	81
146	A Translational Rodent Assay of Affective Biases in Depression and Antidepressant Therapy. Neuropsychopharmacology, 2013, 38, 1625-1635.	5.4	81
147	A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers. Journal of Psychopharmacology, 2007, 21, 42-49.	4.0	80
148	A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy. Frontiers in Psychiatry, 2019, 10, 138.	2.6	80
149	L-Tryptophan and prolactin release: Evidence for interaction between 5-HT1 and 5-HT2 receptors. Human Psychopharmacology, 1986, 1, 93-97.	1.5	78
150	Functional connectivity analysis of the neural circuits of opiate craving: "more―rather than "different�. NeuroImage, 2003, 20, 1964-1970.	4.2	78
151	A Lifetime Prevalence of Comorbidity Between Bipolar Affective Disorder and Anxiety Disorders: A Meta-analysis of 52 Interview-based Studies of Psychiatric Population. EBioMedicine, 2015, 2, 1405-1419.	6.1	78
152	Cerebral blood flow predicts differential neurotransmitter activity. Scientific Reports, 2018, 8, 4074.	3.3	78
153	Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. Frontiers in Pharmacology, 2021, 12, 788155.	3.5	77
154	Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. Journal of Clinical Pathology, 2010, 63, 156-164.	2.0	76
155	The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. International Journal of Neuropsychopharmacology, 2014, 17, 527-540.	2.1	75
156	That warm fuzzy feeling: brain serotonergic neurons and the regulation of emotion. Journal of Psychopharmacology, 2009, 23, 392-400.	4.0	74
157	Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. British Journal of Psychiatry, 2002, 180, 528-535.	2.8	73
158	Does the Brain Noradrenaline Network Mediate the Effects of the CO2 Challenge?. Journal of Psychopharmacology, 2003, 17, 252-259.	4.0	73
159	Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo11C-BU99008 PET study. Brain, 2019, 142, 3116-3128.	7.6	73
160	The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to l-tryptophan. Psychopharmacology, 1987, 93, 416-20.	3.1	72
161	Case History 3. Human Psychopharmacology, 1997, 12, S39-S40.	1.5	72
162	Novel Selective Compounds for the Investigation of Imidazoline Receptorsa. Annals of the New York Academy of Sciences, 1999, 881, 81-91.	3.8	72

#	Article	IF	CITATIONS
163	Generalized anxiety disorder: A comorbid disease. European Neuropsychopharmacology, 2006, 16, S109-S118.	0.7	72
164	Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge. NeuroImage, 2010, 52, 1521-1527.	4.2	72
165	Biological markers of generalized anxiety disorder. Dialogues in Clinical Neuroscience, 2017, 19, 147-158.	3.7	72
166	<i>In vivo</i> imaging of microglial activation by positron emission tomography with <scp>[<sup>11</sup>C]PBR28</scp> in the <scp>5XFAD</scp> model of <scp>A</scp> lzheimer's disease. Glia, 2016, 64, 993-1006.	4.9	71
167	Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites. Journal of Pharmacology and Experimental Therapeutics, 1995, 272, 681-8.	2.5	71
168	Harms associated with psychoactive substances: findings of the UK National Drug Survey. Journal of Psychopharmacology, 2010, 24, 147-153.	4.0	70
169	Psychedelic drugs—a new era in†psychiatry?. Dialogues in Clinical Neuroscience, 2019, 21, 139-147.	3.7	70
170	Death and Dependence: Current Controversies over the Selective Serotonin Reuptake Inhibitors. Journal of Psychopharmacology, 2003, 17, 355-364.	4.0	69
171	User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study. Journal of Substance Use, 2010, 15, 283-300.	0.7	69
172	Brain opioid receptor binding in early abstinence from opioid dependence. British Journal of Psychiatry, 2007, 191, 63-69.	2.8	68
173	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry, 2022, 27, 1286-1299.	7.9	68
174	Does alcohol increase the risk of overdose death: the need for a translational approach. Addiction, 2008, 103, 1060-1062.	3.3	67
175	The role of the opioid system in alcohol dependence. Journal of Psychopharmacology, 2014, 28, 8-22.	4.0	67
176	Using [11C]Diprenorphine to Image Opioid Receptor Occupancy by Methadone in Opioid Addiction: Clinical and Preclinical Studies. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 309-315.	2.5	66
177	First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. Journal of Psychopharmacology, 2021, 35, 375-383.	4.0	66
178	Saccadic eye movement parameters in normal subjects. Electroencephalography and Clinical Neurophysiology, 1993, 86, 69-74.	0.3	65
179	Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatrica Scandinavica, 1997, 96, 31-37.	4.5	64
180	Brain dopamine response in human opioid addiction. British Journal of Psychiatry, 2008, 193, 65-72.	2.8	64

#	Article	IF	CITATIONS
181	A plan for mental illness. Nature, 2012, 483, 269-269.	27.8	64
182	The use of benzodiazepines in anxiety and other disorders. European Neuropsychopharmacology, 1999, 9, S407-S412.	0.7	63
183	Substitution therapy for alcoholism: time for a reappraisal?. Journal of Psychopharmacology, 2012, 26, 205-212.	4.0	63
184	Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology, 2018, 235, 459-466.	3.1	62
185	Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. European Neuropsychopharmacology, 2009, 19, 451-456.	0.7	61
186	Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: An [11C]diprenorphine PET study. European Neuropsychopharmacology, 2009, 19, 740-748.	0.7	61
187	Evaluation of <sup>11</sup> C-BU99008, a PET Ligand for the Imidazoline <sub>2</sub> Binding Site in Human Brain. Journal of Nuclear Medicine, 2018, 59, 1597-1602.	5.0	61
188	Doing it by numbers: A simple approach to reducing the harms of alcohol. Journal of Psychopharmacology, 2014, 28, 3-7.	4.0	60
189	History of cannabis use is not associated with alterations in striatal dopamine D <sub>2</sub> /D <sub>3</sub> receptor availability. Journal of Psychopharmacology, 2012, 26, 144-149.	4.0	57
190	The hidden third: improving outcome in treatment-resistant depression. Journal of Psychopharmacology, 2012, 26, 587-602.	4.0	56
191	Generic legislation of new psychoactive drugs. Journal of Psychopharmacology, 2013, 27, 317-324.	4.0	56
192	Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. British Journal of Psychiatry, 2011, 198, 464-471.	2.8	55
193	Preliminary evidence of anxiolytic effects of the CRF <sub>1</sub> receptor antagonist R317573 in the 7.5% CO <sub>2</sub> proof-of-concept experimental model of human anxiety. Journal of Psychopharmacology, 2011, 25, 1199-1206.	4.0	55
194	Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Psychopharmacology, 2014, 231, 2921-2931.	3.1	55
195	In vitro and ex vivo distribution of [3H]harmane, an endogenous β-carboline, in rat brain. Neuropharmacology, 2006, 50, 269-276.	4.1	53
196	Effects of stressful life events, maternal depression and 5â€HTTLPR genotype on emotional symptoms in preâ€adolescent children. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 670-682.	1.7	53
197	In Vivo Imaging of Cerebral Dopamine D3 Receptors in Alcoholism. Neuropsychopharmacology, 2014, 39, 1703-1712.	5.4	53
198	Distinct Neuropsychological Mechanisms May Explain Delayed- Versus Rapid-Onset Antidepressant Efficacy. Neuropsychopharmacology, 2015, 40, 2165-2174.	5.4	53

#	Article	IF	CITATIONS
199	GABA-A receptor differences in schizophrenia: a positron emission tomography study using [11C]Ro154513. Molecular Psychiatry, 2021, 26, 2616-2625.	7.9	53
200	The role of dopamine and norepinephrine in depression and antidepressant treatment. Journal of Clinical Psychiatry, 2006, 67 Suppl 6, 3-8.	2.2	53
201	[3H]2-(2-Benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I2 receptors. European Journal of Pharmacology, 1996, 304, 221-229.	3.5	52
202	Voluntary exercise alters GABAA receptor subunit and glutamic acid decarboxylase-67 gene expression in the rat forebrain. Journal of Psychopharmacology, 2010, 24, 745-756.	4.0	52
203	Noradrenergic mechanisms in the prefrontal cortex. Journal of Psychopharmacology, 1997, 11, 163-168.	4.0	51
204	Effects of acute tyrosine/phenylalanine depletion on the selective processing of smoking-related cues and the relative value of cigarettes in smokers. Psychopharmacology, 2008, 196, 611-621.	3.1	51
205	A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers. Psychopharmacology, 2007, 191, 943-950.	3.1	50
206	The Pharmacology of Anxiety. Current Topics in Behavioral Neurosciences, 2009, 2, 303-330.	1.7	50
207	GABAA receptors: subtypes, regional distribution, and function. Journal of Clinical Sleep Medicine, 2006, 2, S7-11.	2.6	50
208	Depleting Serotonin Enhances Both Cardiovascular and Psychological Stress Reactivity in Recovered Patients With Anxiety Disorders. Journal of Clinical Psychopharmacology, 2006, 26, 414-418.	1.4	48
209	Illegal Drugs Laws: Clearing a 50-Year-Old Obstacle to Research. PLoS Biology, 2015, 13, e1002047.	5.6	48
210	Adult night terrors and paroxetine. Lancet, The, 1997, 350, 185.	13.7	47
211	GABA-benzodiazepine receptor function in alcohol dependence: a combined 11C-flumazenil PET and pharmacodynamic study. Psychopharmacology, 2005, 180, 595-606.	3.1	47
212	A [ <sup>11</sup> C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced α5 benzodiazepine receptors in limbic regions. Journal of Psychopharmacology, 2012, 26, 273-281.	4.0	47
213	International Consensus Statement on Major Depressive Disorder. Journal of Clinical Psychiatry, 2010, 71, e08.	2.2	47
214	Panic attacks and alcohol withdrawal: Can subjects differentiate the symptoms?. Biological Psychiatry, 1988, 24, 240-243.	1.3	46
215	Increased sympathetic response to standing in panic disorder. Psychiatry Research, 2003, 118, 69-79.	3.3	46
216	Benzodiazepine Site Pharmacokinetic/Pharmacodynamic Quantification in Man: Direct Measurement of Drug Occupancy and Effects on the Human Brain In Vivo. Neuropharmacology, 1996, 35, 1483-1491.	4.1	45

#	Article	IF	CITATIONS
217	The neurobiology of social phobia. European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, S11-S18.	3.2	45
218	Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology, 2003, 167, 195-202.	3.1	45
219	The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability. Journal of Psychopharmacology, 2011, 25, 1562-1567.	4.0	45
220	Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open, 2022, 8, e19.	0.7	45
221	Beyond psychoanaleptics – can we improve antidepressant drug nomenclature?. Journal of Psychopharmacology, 2009, 23, 343-345.	4.0	44
222	Evaluation of <sup>11</sup> C-BU99008, a PET Ligand for the Imidazoline <sub>2</sub> Binding Sites in Rhesus Brain. Journal of Nuclear Medicine, 2014, 55, 838-844.	5.0	44
223	A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation. International Journal of Drug Policy, 2018, 56, 144-152.	3.3	44
224	Imidazoline binding sites in Huntington's and Parkinson's disease putamen. European Journal of Pharmacology, 1996, 301, R19-R21.	3.5	43
225	Endogenous Â-Carbolines as Clonidine-Displacing Substances. Annals of the New York Academy of Sciences, 2003, 1009, 157-166.	3.8	43
226	Alcohol Hangover: Underlying Biochemical, Inflammatory and Neurochemical Mechanisms. Alcohol and Alcoholism, 2019, 54, 196-203.	1.6	43
227	Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load. Molecular Psychiatry, 2021, 26, 5848-5855.	7.9	43
228	A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO2 models of experimental human anxiety. Journal of Psychopharmacology, 2009, 23, 117-122.	4.0	42
229	Serotonin and Sensitivity to Trauma-Related Exposure in Selective Serotonin Reuptake Inhibitors-Recovered Posttraumatic Stress Disorder. Biological Psychiatry, 2009, 66, 17-24.	1.3	42
230	Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse, 2011, 65, 257-259.	1.2	42
231	Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2â€(4,5â€Dihydroâ€1 <i>H</i> â€imidazolâ€2â€yl)â€1―methylâ€1 <i>H</i> â€i imidazoline <sub>2</sub> binding site. Synapse, 2012, 66, 542-551.	ndole)), for	the42
232	Acute increases in synaptic GABA detectable in the living human brain: A [11C]Ro15-4513 PET study. NeuroImage, 2014, 99, 158-165.	4.2	42
233	LSD alters eyesâ€closed functional connectivity within the early visual cortex in a retinotopic fashion. Human Brain Mapping, 2016, 37, 3031-3040.	3.6	42
234	LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm. Neuropharmacology, 2018, 142, 251-262.	4.1	42

#	Article	IF	CITATIONS
235	Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics. Neuropharmacology, 2021, 191, 108586.	4.1	42
236	Gender differences in brain serotonin transporter availability in panic disorder. Journal of Psychopharmacology, 2011, 25, 952-959.	4.0	41
237	E-cigarettes are less harmful than smoking. Lancet, The, 2016, 387, 1160-1162.	13.7	41
238	BAP Position Statement: Off-label prescribing of psychotropic medication to children and adolescents. Journal of Psychopharmacology, 2016, 30, 416-421.	4.0	41
239	GABA <sub>A</sub> receptor availability is not altered in adults with autism spectrum disorder or in mouse models. Science Translational Medicine, 2018, 10, .	12.4	41
240	Sleep changes during long-term treatment of depression with fluvoxamine - a home-based study. Psychopharmacology, 2000, 149, 360-365.	3.1	40
241	Naloxone displacement at opioid receptor sites measured in vivo in the human brain. European Journal of Pharmacology, 2003, 459, 217-219.	3.5	40
242	A placebo-controlled investigation of synaesthesia-like experiences under LSD. Neuropsychologia, 2016, 88, 28-34.	1.6	40
243	Identification of ligands selective for central I2-imidazoline binding sites. Neurochemistry International, 1997, 30, 47-53.	3.8	39
244	Treatment of depression and concomitant anxiety. European Neuropsychopharmacology, 2000, 10, S433-S437.	0.7	39
245	MDMA, politics and medical research: Have we thrown the baby out with the bathwater?. Journal of Psychopharmacology, 2007, 21, 787-791.	4.0	39
246	Addiction: the clinical interface. British Journal of Pharmacology, 2008, 154, 397-405.	5.4	39
247	Antidepressants and the adolescent brain. Journal of Psychopharmacology, 2015, 29, 545-555.	4.0	39
248	Alcohol: the drug. British Medical Bulletin, 1994, 50, 5-17.	6.9	38
249	Death by tricyclic: the real antidepressant scandal?. Journal of Psychopharmacology, 2005, 19, 123-124.	4.0	38
250	Inhibition of Central Monoamine Oxidase by Imidazoline2 Site-Selective Ligands. Annals of the New York Academy of Sciences, 1999, 881, 114-117.	3.8	37
251	Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. Journal of Psychopharmacology, 2013, 27, 771-778.	4.0	37
252	Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. Journal of Affective Disorders, 2018, 230, 84-86.	4.1	37

#	Article	IF	CITATIONS
253	Harmane and Harmalan Are Bioactive Components of Classical Clonidine-Displacing Substanceâ€. Biochemistry, 2004, 43, 16385-16392.	2.5	36
254	Validating the inhalation of 7.5% CO <sub>2</sub> in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD). Journal of Psychopharmacology, 2011, 25, 1192-1198.	4.0	36
255	So near yet so far: why won't the UK prescribe medical cannabis?. BMJ Open, 2020, 10, e038687.	1.9	36
256	A pilot controlled study of the effects of flumazenil in posttraumatic stress disorder. Biological Psychiatry, 1997, 41, 988-990.	1.3	35
257	Potential Novel Anxiolytic Drugs. Current Pharmaceutical Design, 2008, 14, 3534-3546.	1.9	35
258	Increased serum free tryptophan in patients with diarrhea-predominant irritable bowel syndrome. Nutrition Research, 2010, 30, 678-688.	2.9	35
259	Elevating Endogenous GABA Levels with GAT-1 Blockade Modulates Evoked but Not Induced Responses in Human Visual Cortex. Neuropsychopharmacology, 2013, 38, 1105-1112.	5.4	35
260	Neuroscience-based Nomenclature (NbN) for <i>Journal of Psychopharmacology</i> . Journal of Psychopharmacology, 2016, 30, 413-415.	4.0	35
261	A point mutation in the ion conduction pore of AMPA receptor GRIA3 causes dramatically perturbed sleep patterns as well as intellectual disability. Human Molecular Genetics, 2017, 26, 3869-3882.	2.9	35
262	Strain differences in response to a benzodiazepine receptor inverse agonist (FG 7142) in mice. Psychopharmacology, 1988, 94, 335-6.	3.1	34
263	Anxiolytic Potential of Benzodiazepine Receptor Partial Agonists. CNS Drugs, 1994, 1, 305-315.	5.9	34
264	Anti-oxidant vitamins and mental performance of the elderly. Human Psychopharmacology, 1999, 14, 459-471.	1.5	34
265	Differences between magnetoencephalographic (MEG) spectral profiles of drugs acting on GABA at synaptic and extrasynaptic sites: A study in healthy volunteers. Neuropharmacology, 2015, 88, 155-163.	4.1	34
266	Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge. Neuropsychopharmacology, 2020, 45, 804-810.	5.4	34
267	Anhedonia and chronic mild stress model in depression. Psychopharmacology, 1997, 134, 333-336.	3.1	33
268	The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans. Journal of Psychopharmacology, 2005, 19, 609-613.	4.0	33
269	Acute Tryptophan Depletion Alters Gastrointestinal and Anxiety Symptoms in Irritable Bowel Syndrome. American Journal of Gastroenterology, 2006, 101, 2582-2587.	0.4	33
270	A pilot study of the effectiveness of d-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects. Psychopharmacology, 2011, 216, 121-129.	3.1	33

#	Article	IF	CITATIONS
271	Characterisation of the Contribution of the GABA-Benzodiazepine α1 Receptor Subtype to [ <sup>11</sup> C]Ro15-4513 PET Images. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 731-744.	4.3	33
272	Neuroimaging of Serotonin System in Anxiety Disorders. Current Pharmaceutical Design, 2012, 18, 5699-5708.	1.9	33
273	Antidepressant drug development: Focus on triple monoamine reuptake inhibition. Journal of Psychopharmacology, 2015, 29, 526-544.	4.0	33
274	Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study― Frontiers in Psychiatry, 2021, 12, 735523.	2.6	33
275	Reduced thalamic grey matter volume in opioid dependence is influenced by degree of alcohol use: a voxel-based morphometry study. Journal of Psychopharmacology, 2008, 22, 7-10.	4.0	32
276	Identification of an imidazoline binding protein: Creatine kinase and an imidazoline-2 binding site. Brain Research, 2009, 1279, 21-28.	2.2	32
277	Significant reductions in human visual gamma frequency by the gaba reuptake inhibitor tiagabine revealed by robust peak frequency estimation. Human Brain Mapping, 2016, 37, 3882-3896.	3.6	32
278	Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study. Biological Psychiatry, 2017, 81, 941-948.	1.3	32
279	Effects of 7.5% CO2 challenge in generalized anxiety disorder. Journal of Psychopharmacology, 2011, 25, 43-51.	4.0	31
280	Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression. Journal of Psychopharmacology, 2013, 27, 915-920.	4.0	31
281	CNS drug development in Europe — Past progress and future challenges. Neurobiology of Disease, 2014, 61, 6-20.	4.4	31
282	Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives. NeuroImage, 2019, 200, 281-291.	4.2	31
283	DMT alters cortical travelling waves. ELife, 2020, 9, .	6.0	31
284	Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers. Journal of Psychopharmacology, 2001, 15, 9-12.	4.0	30
285	Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram. European Neuropsychopharmacology, 2004, 14, 367-372.	0.7	30
286	d-Cycloserine and performance under different states of anxiety in healthy volunteers. Psychopharmacology, 2007, 193, 579-585.	3.1	30
287	Imaging Imidazoline-I <sub>2</sub> Binding Sites in Porcine Brain Using <sup>11</sup> C-BU99008. Journal of Nuclear Medicine, 2013, 54, 139-144.	5.0	30
288	Naltrexone ameliorates functional network abnormalities in alcoholâ€dependent individuals. Addiction Biology, 2018, 23, 425-436.	2.6	30

#	Article	IF	CITATIONS
289	Characterisation of the effects of caffeine on sleep in the rat: a potential model of sleep disruption. Journal of Psychopharmacology, 2009, 23, 475-486.	4.0	29
290	GABAergic control of novelty stress-responsive epigenetic and gene expression mechanisms in the rat dentate gyrus. European Neuropsychopharmacology, 2011, 21, 316-324.	0.7	29
291	Imaging Endogenous Opioid Peptide Release with [ <sup>11</sup> C]Carfentanil and [ <sup>3</sup> H]Diprenorphine: Influence of Agonist-Induced Internalization. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1604-1612.	4.3	29
292	Moclobemide in the treatment of social phobia. International Clinical Psychopharmacology, 1996, 11, 77-82.	1.7	28
293	2-(4,5-Dihydro-1H-imidazol-2-yl)indazole (indazim) derivatives as selective I2 imidazoline receptor ligands. European Journal of Pharmaceutical Sciences, 2003, 20, 201-208.	4.0	28
294	Low Sensitivity of the Positron Emission Tomography Ligand [11C]Diprenorphine to Agonist Opiates. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 661-667.	2.5	28
295	Effects on sleep stages and microarchitecture of caffeine and its combination with zolpidem or trazodone in healthy volunteers. Journal of Psychopharmacology, 2009, 23, 487-494.	4.0	28
296	Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence. Neuropsychopharmacology, 2017, 42, 1049-1057.	5.4	28
297	Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?. Journal of Psychopharmacology, 2022, 36, 6-11.	4.0	28
298	Alcohol and the Brain. Nutrients, 2021, 13, 3938.	4.1	28
299	The feasibility of abrupt methadone-buprenorphine transfer in British opiate addicts in an outpatient setting. Addiction Biology, 1997, 2, 191-200.	2.6	27
300	Imagery of craving in opiate addicts undergoing detoxification. Drug and Alcohol Dependence, 1997, 48, 25-31.	3.2	27
301	Flumazenil challenge in social phobia. , 2000, 11, 27-30.		27
302	Making a medicine out of MDMA. British Journal of Psychiatry, 2015, 206, 4-6.	2.8	27
303	The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description. Journal of Psychopharmacology, 2015, 29, 943-960.	4.0	27
304	Medical cannabis in the UK: From principle to practice. Journal of Psychopharmacology, 2020, 34, 931-937.	4.0	27
305	The effects of clonidine on cardiovascular responses to standing in healthy volunteers. Clinical Autonomic Research, 1995, 5, 171-177.	2.5	26
306	Sleep and daytime sleepiness the next day following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers. Journal of Psychopharmacology, 2000, 14, 378-386.	4.0	26

#	Article	IF	CITATIONS
307	Panic and hypertension: brothers in arms through 5-HT?. Journal of Psychopharmacology, 2007, 21, 563-566.	4.0	26
308	Management of insomnia: treatments and mechanisms. British Journal of Psychiatry, 2007, 191, 195-197.	2.8	26
309	Attacks on antidepressants: signs of deep-seated stigma?. Lancet Psychiatry,the, 2014, 1, 102-104.	7.4	26
310	Impulsivity in abstinent alcohol and polydrug dependence: a multidimensional approach. Psychopharmacology, 2016, 233, 1487-1499.	3.1	26
311	Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use. Current Opinion in Behavioral Sciences, 2017, 13, 71-76.	3.9	26
312	Acute naltrexone does not remediate frontoâ€striatal disturbances in alcoholic and alcoholic polysubstanceâ€dependent populations during a monetary incentive delay task. Addiction Biology, 2017, 22, 1576-1589.	2.6	26
313	Was it a vision or a waking dream?. Frontiers in Psychology, 2014, 5, 255.	2.1	26
314	Why doctors have a moral imperative to prescribe and support medical cannabis—an essay by David Nutt. BMJ, The, 0, , n3114.	6.0	26
315	Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology, 2003, 61, 1161-1161.	1.1	25
316	Altered Insula Connectivity under MDMA. Neuropsychopharmacology, 2017, 42, 2152-2162.	5.4	25
317	Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. Scientific Reports, 2018, 8, 8236.	3.3	25
318	Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21. Psychopharmacology, 2022, 239, 1147-1155.	3.1	25
319	Development and validation of the Generalized Anxiety Disorder Inventory (GADI). Journal of Psychopharmacology, 2007, 21, 145-152.	4.0	24
320	Establishing non-inferiority in treatment trials in psychiatry — guidelines from an Expert Consensus Meeting. Journal of Psychopharmacology, 2008, 22, 409-416.	4.0	24
321	Investigating expectation and reward in human opioid addiction with [ <sup>11</sup> <scp>C</scp> ]raclopride <scp>PET</scp> . Addiction Biology, 2014, 19, 1032-1040.	2.6	24
322	Deaths from "legal highs― a problem of definitions. Lancet, The, 2014, 383, 952.	13.7	24
323	Semantic activation in LSD: evidence from picture naming. Language, Cognition and Neuroscience, 2016, 31, 1320-1327.	1.2	24
324	Evidence for GABAâ€A receptor dysregulation in gambling disorder: correlation with impulsivity. Addiction Biology, 2017, 22, 1601-1609.	2.6	24

#	Article	IF	CITATIONS
325	A tale of two Es. Journal of Psychopharmacology, 2006, 20, 315-317.	4.0	23
326	GENetic and clinical Predictors Of treatment response in Depression: the GenPod randomised trial protocol. Trials, 2008, 9, 29.	1.6	23
327	GABA-A receptors and the response to CO2 inhalation — A translational trans-species model of anxiety?. Pharmacology Biochemistry and Behavior, 2008, 90, 51-57.	2.9	23
328	The effects of single dose anxiolytic medication on the CO2 models of anxiety: differentiation of subjective and objective measures. Journal of Psychopharmacology, 2010, 24, 649-656.	4.0	23
329	LET NOT THE BEST BE THE ENEMY OF THE GOOD. Addiction, 2011, 106, 1892-1893.	3.3	23
330	No psychiatry without psychopharmacology. British Journal of Psychiatry, 2011, 199, 263-265.	2.8	23
331	Sleep and its disorders in translational medicine. Journal of Psychopharmacology, 2011, 25, 1226-1234.	4.0	23
332	Severity of depression and response to antidepressants: GENPOD randomised controlled trial. British Journal of Psychiatry, 2012, 200, 130-136.	2.8	23
333	History of cigarette smoking is associated with higher limbic GABAA receptor availability. NeuroImage, 2013, 69, 70-77.	4.2	23
334	First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants. BMJ Case Reports, 2019, 12, e230109.	0.5	23
335	Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals. Molecular Psychiatry, 2020, 25, 1749-1758.	7.9	23
336	A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products. Cannabis and Cannabinoid Research, 2022, 7, 482-500.	2.9	23
337	Opiate agonists and antagonists modulate taste perception in opiate-maintained and recently detoxified subjects. Journal of Psychopharmacology, 2013, 27, 265-275.	4.0	22
338	The Hamilton Depression Scaleaccelerator or break on antidepressant drug discovery?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 119-120.	1.9	22
339	3-Methyl-methcathinone: Pharmacokinetic profile evaluation in pigs in relation to pharmacodynamics. Journal of Psychopharmacology, 2015, 29, 734-743.	4.0	22
340	Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression. European Neuropsychopharmacology, 2016, 26, 1475-1483.	0.7	22
341	The clinical use of buprenorphine in opiate addiction: evidence and practice. Acta Neuropsychiatrica, 2004, 16, 246-274.	2.1	21
342	Imaging alcohol cue exposure in alcohol dependence using a PET15O-H2O paradigm: results from a pilot study. Addiction Biology, 2006, 11, 107-115.	2.6	21

#	Article	IF	CITATIONS
343	Current and former ecstasy users report different sleep to matched controls: a web-based questionnaire study. Journal of Psychopharmacology, 2009, 23, 249-257.	4.0	21
344	Emotional symptoms in children: The effect of maternal depression, life events, and COMT genotype. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 209-218.	1.7	21
345	Evidence for serotonin function as a neurochemical difference between fear and anxiety disorders in humans?. Journal of Psychopharmacology, 2015, 29, 1061-1069.	4.0	21
346	Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. Journal of Psychopharmacology, 2015, 29, 1085-1091.	4.0	21
347	Biological predictors of pharmacological therapy in anxiety disorders. Dialogues in Clinical Neuroscience, 2015, 17, 305-317.	3.7	21
348	Evaluation of [ O-methyl - 11 C]RS-15385-197 as a positron emission tomography radioligand for central α 2 -adrenoceptors. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 475-484.	6.4	20
349	Anxiety and OCD – the chicken or the egg?. Journal of Psychopharmacology, 2006, 20, 729-731.	4.0	20
350	Anxiety - bridging the heart/mind divide. Journal of Psychopharmacology, 2010, 24, 633-638.	4.0	20
351	Effects of 7.5% CO2inhalation on allocation of spatial attention to facial cues of emotional expression. Cognition and Emotion, 2011, 25, 626-638.	2.0	20
352	Noradrenergic function in generalized anxiety disorder: impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge. Journal of Psychopharmacology, 2011, 25, 78-86.	4.0	20
353	The entropic tongue: Disorganization of natural language under LSD. Consciousness and Cognition, 2021, 87, 103070.	1.5	20
354	NICE: The National Institute of Clinical Excellence - or Eccentricity? Reflections on the Z-drugs as hypnotics. Journal of Psychopharmacology, 2005, 19, 125-127.	4.0	19
355	Alcohol alternatives – a goal for psychopharmacology?. Journal of Psychopharmacology, 2006, 20, 318-320.	4.0	19
356	Evaluation of an operant successive negative contrast task as a method to study affective state in rodents. Behavioural Brain Research, 2012, 234, 155-160.	2.2	19
357	Relationship between astrocyte reactivity, using novel 11C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals. Molecular Psychiatry, 2022, 27, 2019-2029.	7.9	19
358	Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. Journal of Neurochemistry, 2006, 96, 1551-1559.	3.9	18
359	Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder. Psychopharmacology, 2010, 208, 223-232.	3.1	18
360	Influence of different cellular environments on [ <sup>3</sup> H]DASB radioligand binding. Synapse, 2012, 66, 1035-1039.	1.2	18

#	Article	IF	CITATIONS
361	Validated Method for the Quantification of Baclofen in Human Plasma Using Solid-Phase Extraction and Liquid Chromatography–Tandem Mass Spectrometry. Journal of Analytical Toxicology, 2016, 40, 117-123.	2.8	18
362	Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery. Translational Psychiatry, 2017, 7, e1054-e1054.	4.8	18
363	Using Baclofen to Explore GABA-B Receptor Function in Alcohol Dependence: Insights From Pharmacokinetic and Pharmacodynamic Measures. Frontiers in Psychiatry, 2018, 9, 664.	2.6	18
364	Acute and chronic idazoxan in normal volunteers: biochemical, physiological and psychological effects. Journal of Psychopharmacology, 1991, 5, 396-403.	4.0	17
365	Making sense of GABAA receptor subtypes: is a new nomenclature needed?. Journal of Psychopharmacology, 2005, 19, 219-220.	4.0	17
366	Dopamine transporter binding in females with panic disorder may vary with clinical status. Journal of Psychiatric Research, 2010, 44, 56-59.	3.1	17
367	The full cost and burden of disorders of the brain in Europe exposed for the first time. European Neuropsychopharmacology, 2011, 21, 715-717.	0.7	17
368	Through a glass darkly: can we improve clarity about mechanism and aims of medications in drug and alcohol treatments?. Journal of Psychopharmacology, 2012, 26, 199-204.	4.0	17
369	Ranking the harm of non-medically used prescription opioids in theÂUK. Regulatory Toxicology and Pharmacology, 2015, 73, 999-1004.	2.7	17
370	An effective hangover treatment: Friend or foe?. Drug Science, Policy and Law, 2017, 3, 205032451774103.	1.3	17
371	Rationale for, Barriers to, and Appropriate Medication for the Long-Term Treatment of Depression. Journal of Clinical Psychiatry, 2010, 71, e02.	2.2	17
372	A pharmacodynamic study of the α2-adrenergic receptor antagonist ethoxyidazoxan in healthy volunteers. Clinical Pharmacology and Therapeutics, 1994, 56, 420-429.	4.7	16
373	Distribution of [3H]BU224, a selective imidazoline I2 binding site ligand, in rat brain. European Journal of Pharmacology, 2002, 450, 55-60.	3.5	16
374	Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone. Journal of Sleep Research, 2009, 18, 342-348.	3.2	16
375	Nutt damage – Author's reply. Lancet, The, 2010, 375, 724.	13.7	16
376	The effects of 7.5% carbon dioxide inhalation on task performance in healthy volunteers. Journal of Psychopharmacology, 2012, 26, 487-496.	4.0	16
377	Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety?. Journal of Psychopharmacology, 2013, 27, 119-122.	4.0	16
378	The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description. Journal of Psychopharmacology, 2017, 31, 3-16.	4.0	16

#	Article	IF	CITATIONS
379	The psychobiology of posttraumatic stress disorder. Journal of Clinical Psychiatry, 2000, 61 Suppl 5, 24-9; discussion 30-2.	2.2	16
380	Probes for imidazoline binding sites: synthesis and evaluation of a selective, irreversible I 2 ligand. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 605-607.	2.2	15
381	Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. Psychopharmacology, 2006, 186, 107-112.	3.1	15
382	Government vs science over drug and alcohol policy. Lancet, The, 2009, 374, 1731-1733.	13.7	15
383	What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology. Journal of Psychopharmacology, 2010, 24, 1137-1141.	4.0	15
384	Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation?. Journal of Psychopharmacology, 2012, 26, 213-220.	4.0	15
385	Optimising <scp>PET</scp> approaches to measuring 5â€ <scp>HT</scp> release in human brain. Synapse, 2015, 69, 505-511.	1.2	15
386	Behavioural tasks sensitive to acute abstinence and predictive of smoking cessation success: a systematic review and metaâ€analysis. Addiction, 2016, 111, 2134-2144.	3.3	15
387	Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment. Journal of Psychopharmacology, 2021, 35, 547-555.	4.0	15
388	The Neurochemistry of Addiction. Human Psychopharmacology, 1997, 12, S53-S58.	1.5	14
389	Assessment of GABA A benzodiazepine receptor (GBzR) sensitivity in patients on benzodiazepines. Psychopharmacology, 1999, 146, 180-184.	3.1	14
390	5-Isothiocyanato-2-benzofuranyl-2-imidazoline (BU99006) an irreversible imidazoline2 binding site ligand: in vitro and in vivo characterisation in rat brain. Neuropharmacology, 2002, 43, 75-83.	4.1	14
391	Characterization of [3H]Harmane Binding to Rat Whole Brain Membranes. Annals of the New York Academy of Sciences, 2003, 1009, 175-179.	3.8	14
392	Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls. Psychopharmacology, 2009, 206, 187-196.	3.1	14
393	A U-shaped relationship between systolic blood pressure and panic symptoms: the HUNT study. Psychological Medicine, 2012, 42, 1969-1976.	4.5	14
394	Resting state synchrony in anxiety-related circuits of abstinent alcohol-dependent patients. American Journal of Drug and Alcohol Abuse, 2013, 39, 433-440.	2.1	14
395	Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a doubleâ€blind, placeboâ€controlled study of orthostatic challenge, blood pressure and heart rate. Human Psychopharmacology, 2013, 28, 562-575.	1.5	14
396	Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. Journal of Psychopharmacology, 2016, 30, 1163-1164.	4.0	14

#	Article	IF	CITATIONS
397	Effect of short-term escitalopram treatment on neural activation during emotional processing. Journal of Psychopharmacology, 2016, 30, 33-39.	4.0	14
398	Inverse agonists – What do they mean for psychiatry?. European Neuropsychopharmacology, 2017, 27, 87-90.	0.7	14
399	Manifesto for an international digital mental health network. Digital Psychiatry, 2019, 2, 14-24.	2.1	14
400	Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test. Addiction Biology, 2003, 8, 59-66.	2.6	13
401	In vitro and in vivo effect of BU99006 (5-isothiocyanato-2-benzofuranyl-2-imidazoline) on I2 binding in relation to MAO: Evidence for two distinct I2 binding sites. Neuropharmacology, 2007, 52, 395-404.	4.1	13
402	Why does the world have such a `down' on antidepressants?. Journal of Psychopharmacology, 2008, 22, 223-226.	4.0	13
403	Perverse effects of the precautionary principle: how banning mephedrone has unexpected implications for pharmaceutical discovery. Therapeutic Advances in Psychopharmacology, 2011, 1, 35-36.	2.7	13
404	Neuroscience in recession?. Nature Reviews Neuroscience, 2011, 12, 297-302.	10.2	13
405	Elucidation of neurobiology of anxiety disorders in children through pharmacological challenge tests and cortisol measurements: a systematic review. Journal of Psychopharmacology, 2012, 26, 431-442.	4.0	13
406	Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): an example from the GENPOD trial. Psychological Medicine, 2014, 44, 2855-2866.	4.5	13
407	Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs). Journal of Psychopharmacology, 2014, 28, 711-718.	4.0	13
408	The influence of different cellular environments on PET radioligand binding: An application to D2/3-dopamine receptor imaging. Neuropharmacology, 2014, 85, 305-313.	4.1	13
409	Acute effects of cannabis on speech illusions and psychotic-like symptoms: two studies testing the moderating effects of cannabidiol and adolescence. Psychological Medicine, 2021, 51, 2134-2142.	4.5	13
410	Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey. Psychopharmacology, 2022, 239, 1425-1440.	3.1	13
411	A comparison of the effects of phenelzine treatment with moclobemide treatment on cardiovascular reflexes. International Clinical Psychopharmacology, 1995, 10, 229-238.	1.7	12
412	Assessment of GABAABenzodiazepine Receptor (GBzR) Sensitivity in Patients with Alcohol Dependence. Alcohol and Alcoholism, 2008, 43, 614-618.	1.6	12
413	Introduction. The neurobiology of drug addiction: new vistas. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3109-3111.	4.0	12
414	Lamotrigine for attention deficit-hyperactivity disorder comorbid with mood disorders: a case series. Journal of Psychopharmacology, 2014, 28, 282-283.	4.0	12

#	ARTICLE	IF	CITATIONS
415	Î <sup>3</sup> -aminobutyric acid as a metabolite: Interpreting magnetic resonance spectroscopy experiments. Journal of Psychopharmacology, 2016, 30, 422-427.	4.0	12
416	Psychedelics and related drugs: therapeutic possibilities, mechanisms and regulation. Psychopharmacology, 2018, 235, 373-375.	3.1	12
417	First evaluation of PET-based human biodistribution and radiation dosimetry of 11C-BU99008, a tracer for imaging the imidazoline2 binding site. EJNMMI Research, 2018, 8, 71.	2.5	12
418	Acute tryptophan depletion. Part I: rationale and methodology. Australian and New Zealand Journal of Psychiatry, 2005, 39, 558-564.	2.3	12
419	Highlights of the International Consensus Statement on Major Depressive Disorder. Journal of Clinical Psychiatry, 2011, 72, e21.	2.2	12
420	The physical health challenges in patients with severe mental illness: cardiovascular and metabolic risks. Journal of Psychopharmacology, 2010, 24, 1-8.	4.0	11
421	Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic. Journal of Psychopharmacology, 2013, 27, 135-145.	4.0	11
422	New victims of current drug laws. Nature Reviews Neuroscience, 2013, 14, 877-877.	10.2	11
423	Mindâ€altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?. EMBO Reports, 2014, 15, 208-211.	4.5	11
424	Where now for schizophrenia research?. European Neuropsychopharmacology, 2014, 24, 1181-1187.	0.7	11
425	Why Less Is Always More in the Treatment of Alcohol Use Disorders. JAMA Psychiatry, 2019, 76, 359.	11.0	11
426	Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcoholâ€dependent and polysubstanceâ€dependent individuals. European Journal of Neuroscience, 2019, 50, 2311-2321.	2.6	11
427	New psychoactive substances: Pharmacology influencing UK practice, policy and the law. British Journal of Clinical Pharmacology, 2020, 86, 445-451.	2.4	11
428	Imidazoline ligand BU224 reverses cognitive deficits, reduces microgliosis and enhances synaptic connectivity in a mouse model of Alzheimer's disease. British Journal of Pharmacology, 2021, 178, 654-671.	5.4	11
429	Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. Journal of Clinical Psychiatry, 2006, 67 Suppl 6, 46-9.	2.2	11
430	The Effects of Electroconvulsive Therapy on Plasma Insulin and Glucose in Depression. British Journal of Psychiatry, 1992, 161, 94-98.	2.8	10
431	Seizures in a night club. Lancet, The, 2007, 370, 220.	13.7	10
432	The effect of a clinically effective and nonâ€effective dose of lorazepam on 7.5% CO <sub>2</sub> â€induced anxiety. Human Psychopharmacology, 2012, 27, 540-548.	1.5	10

#	Article	IF	CITATIONS
433	Personalized Risk Assessment of Drug-Related Harm Is Associated with Health Outcomes. PLoS ONE, 2013, 8, e79754.	2.5	10
434	Influence of agonist induced internalization on [ <sup>3</sup> H]Ro15â€4513 binding—an application to imaging fluctuations in endogenous GABA with positron emission tomography. Synapse, 2015, 69, 60-65.	1.2	10
435	Using [11C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism. NeuroImage, 2016, 132, 1-7.	4.2	10
436	Why medical cannabis is still out of patients' reach—an essay by David Nutt. BMJ: British Medical Journal, 2019, 365, l1903.	2.3	10
437	Disturbances across whole brain networks during reward anticipation in an abstinent addiction population. NeuroImage: Clinical, 2020, 27, 102297.	2.7	10
438	Effects of classic psychedelic drugs on turbulent signatures in brain dynamics. Network Neuroscience, 2022, 6, 1104-1124.	2.6	10
439	Individual and combined effects of cannabidiol and Δ <sup>9</sup> -tetrahydrocannabinol on striato-cortical connectivity in the human brain. Journal of Psychopharmacology, 2022, 36, 732-744.	4.0	10
440	Are 5-HT receptors or β-adrenoceptors involved in idazoxan-induced food and water intake?. Neuropharmacology, 1992, 31, 1081-1087.	4.1	9
441	A Case Study of the 35% CO2 Challenge. , 0, , 339-357.		9
442	Is the association of hypertension and panic disorder explained by clustering of autonomic panic symptoms in hypertensive patients?. Journal of Affective Disorders, 2008, 111, 344-350.	4.1	9
443	Psychopharmacological characterisation of the successive negative contrast effect in rats. Psychopharmacology, 2015, 232, 2697-2709.	3.1	9
444	Characteristics of People Seeking Prescribed Cannabinoids for the Treatment of Chronic Pain: Evidence From Project Twenty 21. Frontiers in Pain Research, 0, 3, .	2.0	9
445	The effects of the α2-adrenoceptor antagonist idazoxan on sleep in normal volunteers. Journal of Psychopharmacology, 1991, 5, 105-110.	4.0	8
446	Chapter 5.1 Phenomenology of anxiety disorders. Handbook of Behavioral Neuroscience, 2008, , 365-393.	0.7	8
447	Addiction: lifestyle choice or medical diagnosis?. Journal of Evaluation in Clinical Practice, 2013, 19, 493-496.	1.8	8
448	The effect of 6-week treatment with escitalopram on CCK-4 challenge: A placebo-controlled study in CCK-4-sensitive healthy volunteers. European Neuropsychopharmacology, 2013, 23, 645-652.	0.7	8
449	Harmane: An atypical neurotransmitter?. Neuroscience Letters, 2015, 590, 1-5.	2.1	8
450	Concerns regarding conclusions made about LSD-treatments (received 25 October 2016). History of Psychiatry, 2017, 28, 257-260.	0.3	8

#	Article	IF	CITATIONS
451	Cannabis and opioid overdoses: time to move on and examine potential mechanisms. Addiction, 2018, 113, 1551-1552.	3.3	8
452	A multi criteria decision analysis (MCDA) for evaluating and appraising government policy responses to non medical heroin use. International Journal of Drug Policy, 2021, 91, 103180.	3.3	8
453	Acute tryptophan depletion. Part II: clinical effects and implications. Australian and New Zealand Journal of Psychiatry, 2005, 39, 565-574.	2.3	8
454	Management of patients with depression associated with anxiety symptoms. Journal of Clinical Psychiatry, 1997, 58 Suppl 8, 11-6.	2.2	8
455	Care of depressed patients with anxiety symptoms. Journal of Clinical Psychiatry, 1999, 60 Suppl 17, 23-7; discussion 46-8.	2.2	8
456	Debunking the myth of â€~Blue Mondays': No evidence of affect drop after taking clinical MDMA. Journal of Psychopharmacology, 2022, 36, 360-367.	4.0	8
457	Flumazenil and saccadic eye movements in patients with panic disorder and normal controls. Human Psychopharmacology, 1992, 7, 45-50.	1.5	7
458	Antidepressants and mania: To stop or not to stop?. Human Psychopharmacology, 1993, 8, 357-360.	1.5	7
459	Relationship Between Imidazoline2 Sites and Monoamine Oxidase. Annals of the New York Academy of Sciences, 2003, 1009, 353-356.	3.8	7
460	Identification of an I2 Binding Protein From Rabbit Brain. Annals of the New York Academy of Sciences, 2003, 1009, 364-366.	3.8	7
461	2-(4,5-Dihydroimidazol-2-yl)benzimidazoles as highly selective imidazoline I2/adrenergic α2 receptor ligands. Bioorganic and Medicinal Chemistry, 2006, 14, 6679-6685.	3.0	7
462	Prescribing antidepressants post Cipriani et al. Journal of Psychopharmacology, 2009, 23, 865-866.	4.0	7
463	Women with diarrhoea-predominant irritable bowel syndrome show an increased pressure response to 35% carbon dioxide stress challenge. Stress, 2009, 12, 30-36.	1.8	7
464	Rapid tryptophan depletion following cognitive behavioural therapy for panic disorder. Psychopharmacology, 2011, 213, 593-602.	3.1	7
465	On assessing potential efficacy for vortioxetine in generalized anxiety disorder. European Neuropsychopharmacology, 2012, 22, 841-843.	0.7	7
466	The extinction of drugs for clinical research: Can the ECNP medicines chest save them?. European Neuropsychopharmacology, 2014, 24, 487-490.	0.7	7
467	Progress in Mind: Focus on Alcohol Use Disorders, an Elsevier Resource Centre. Psychiatry Research, 2015, 226, 513-514.	3.3	7
468	Imaging and Genetic Approaches to Inform Biomarkers for Anxiety Disorders, Obsessive–Compulsive Disorders, and PSTD. Current Topics in Behavioral Neurosciences, 2018, 40, 219-292.	1.7	7

4

#	Article	IF	CITATIONS
469	Compound asset sharing initiatives between pharmaceutical companies, funding bodies, and academia: Learnings and successes. Pharmacology Research and Perspectives, 2019, 7, e00510.	2.4	7
470	Evidence that imipramine-induced postural hypotension may be centrally mediated. Human Psychopharmacology, 1988, 3, 181-190.	1.5	6
471	In Vivo Estimation of Imidazoline2 Binding Site Turnover. Annals of the New York Academy of Sciences, 2003, 1009, 367-370.	3.8	6
472	New directions in the treatment of anxiety disorders. Expert Opinion on Therapeutic Patents, 2003, 13, 401-423.	5.0	6
473	The Unhappy Saga of `Happy Pills'. Journal of Psychopharmacology, 2003, 17, 251-251.	4.0	6
474	Antagonist—agonist combinations as therapies for heroin addiction: back to the future?. Journal of Psychopharmacology, 2010, 24, 141-145.	4.0	6
475	Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial. Journal of Psychopharmacology, 2012, 26, 663-669.	4.0	6
476	Toxicological evaluation of 5-methoxy-2-aminoindane (MEAI): Binge mitigating agent in development. Toxicology and Applied Pharmacology, 2017, 319, 59-68.	2.8	6
477	Psychopharmacology of benzodiazepines—an update. Human Psychopharmacology, 1995, 10, S1-S14.	1.5	5
478	Comparison of Crude Methanolic CDS Extracts from Various Tissues. Annals of the New York Academy of Sciences, 1999, 881, 92-96.	3.8	5
479	SCIENCE AND NON-SCIENCE IN UK DRUG POLICY. Addiction, 2010, 105, 1154-1154.	3.3	5
480	Effects of 7.5% CO <sub>2</sub> -Induced Anxiety on Individual Performance During a Group Computer Combat Game. Military Psychology, 2013, 25, 615-622.	1.1	5
481	Don't panic. A guide to tryptophan depletion with disorder-specific anxiety provocation. Journal of Psychopharmacology, 2016, 30, 1137-1140.	4.0	5
482	Psychedelics – Re-opening the doors of perception. Neuropharmacology, 2018, 142, 1-6.	4.1	5
483	Should the supply of cannabis be legalised now?. BMJ: British Medical Journal, 2019, 366, 14473.	2.3	5
484	Medical cannabis and epilepsy in the UK – A qualitative analysis of the carers' perspective: "We're asking for quality of life for our children― Drug Science, Policy and Law, 2021, 7, 205032452110349.	1.3	5
485	Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients. BMJ Paediatrics Open, 2021, 5, e001234.	1.4	5

486 Panic Disorder: Clinical Course, Morbidity and Comorbidity. , 0, , 51-79.

#	Article	IF	CITATIONS
487	The Experience Sampling Method in Stress and Anxiety Research. , 0, , 289-306.		4
488	Pharmacological treatment of bipolar disorder. Psychiatry (Abingdon, England), 2007, 6, 305-308.	0.2	4
489	Tryptophan Research in Panic Disorder. International Journal of Tryptophan Research, 2008, 1, IJTR.S929.	2.3	4
490	Massive overuse or appropriate medical intervention? The modern-day use of antidepressants. Current Opinion in Pharmacology, 2012, 12, 109-110.	3.5	4
491	Can Neuroscience Improve Addiction Treatment and Policies?. Public Health Reviews, 2013, 35, .	3.2	4
492	A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers. Human Psychopharmacology, 2014, 29, 163-171.	1.5	4
493	Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective. Journal of Psychopharmacology, 2015, 29, 43-49.	4.0	4
494	A pilot study of the effect of short-term escitalopram treatment on brain metabolites and gamma-oscillations in healthy subjects. Journal of Psychopharmacology, 2016, 30, 579-580.	4.0	4
495	Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial. Journal of Psychopharmacology, 2021, 35, 919-927.	4.0	4
496	Noradrenaline in depression: half a century of progress. Journal of Psychopharmacology, 1997, 11, S3.	4.0	4
497	The Psychobiology of Post-Traumatic Stress Disorder. , 0, , 223-244.		4
498	Generalised Anxiety Disorder. , 0, , 187-204.		3
499	The Pharmacology of Human Anxiety. , 0, , 309-324.		3
500	Learning Perspectives on Anxiety Disorders. , 0, , 245-264.		3
501	Reply to letter by Green, Marsden and Fone (2007) about Sessa and Nutt's editorial (MDMA: baby with) Tj ETQq1	1.0,7843 4.0	14 rgBT /Ov
502	Low serotonergic tone and elevated risk for substance misuse. British Journal of Psychiatry, 2011, 199, 353-354.	2.8	3
503	Pharmacological cognitive enhancement in healthy people: Potential and concerns. Neuropharmacology, 2013, 64, 8-12.	4.1	3
504	Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry,the, 2019, 6, 560-561.	7.4	3

#	Article	IF	CITATIONS
505	Acute acetate administration increases endogenous opioid levels in the human brain: A [ <sup>11</sup> C]carfentanil molecular imaging study. Journal of Psychopharmacology, 2021, 35, 606-610.	4.0	3
506	Neuroreceptor Science. Journal of Clinical Psychopharmacology, 1988, 8, 387???390.	1.4	2
507	Maintenance pharmacotherapy of unipolar depression. Psychiatric Bulletin, 1999, 23, 370-373.	0.3	2
508	Autoradiography of I2 Receptors in Frog Brain. Annals of the New York Academy of Sciences, 1999, 881, 208-211.	3.8	2
509	Paroxetine and its uses in psychiatry. British Journal of Hospital Medicine, 1999, 60, 353-356.	0.2	2
510	The effect of 1-(4,5-dihydro-1H-imidazol-2-yl) isoquinoline on monoamine release and turnover in the rat frontal cortex. Neuroscience Letters, 2007, 422, 109-113.	2.1	2
511	UNDERSTANDING CAUSAL PATHWAYS: A RESPONSE TO THE COMMENTARIES. Addiction, 2008, 103, 1067-1068.	3.3	2
512	The role and basis of the drug laws. Prometheus, 2010, 28, 293-297.	0.4	2
513	Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial. Journal of Affective Disorders, 2014, 163, 40-46.	4.1	2
514	The European College of Neuropsychopharmacology (ECNP) Medicines Chest Initiative: Rationale and Promise. Pharmaceutical Medicine, 2015, 29, 269-273.	1.9	2
515	Psychiatric Drug Discovery and Development. , 2020, , 35-68.		2
516	Pharmacogenomics and Psychopharmacology. , 2020, , 151-202.		2
517	Chronic alcohol exposure differentially modulates structural and functional properties of amygdala: A crossâ€sectional study. Addiction Biology, 2021, 26, e12980.	2.6	2
518	Functional evaluation of NK1 antagonism on cue reactivity in opiate dependence; An fMRI study. Drug and Alcohol Dependence, 2021, 221, 108564.	3.2	2
519	Opioids Neuroimaging. , 2013, , 675-687.		2
520	Efficacy of mirtazapine in clinically relevant subgroups of depressed patients. Depression and Anxiety, 1998, 7 Suppl 1, 7-10.	4.1	2
521	Panic Disorder: Pathogenesis and Treatment. , 0, , 81-103.		1
522	Clinical Testing of Anxiolytic Drugs. , 0, , 325-337.		1

#	Article	IF	CITATIONS
523	Epidemiology of Anxiety Disorders. , 0, , 1-23.		1
524	Rob Kerwin $\hat{a} \in \tilde{a}$ an appreciation. Journal of Psychopharmacology, 2007, 21, 237-237.	4.0	1
525	Reply to OCD letter. Journal of Psychopharmacology, 2008, 22, 338-338.	4.0	1
526	Cardiac slowing and acute tryptophan depletion: a comment on the paper by van der Veen et al Psychopharmacology, 2009, 203, 831-833.	3.1	1
527	Anxiolytics. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 106, 669-679.	1.8	1
528	Brain Imaging in Addiction. , 2012, , 3-25.		1
529	Noradrenaline $\hat{a} \in $ the forgotten amine?. Journal of Psychopharmacology, 2013, 27, 657-658.	4.0	1
530	8. Neurobiologie des troubles anxieux. , 2014, , 69.		1
531	P.6.f.002 Endogenous opioid release in pathological gamblers after an oral amphetamine challenge: a [11C]carfentanil PET study. European Neuropsychopharmacology, 2014, 24, S699-S700.	0.7	1
532	Recommended diagnosis and management of insomnia. The Prescriber, 2014, 25, 12-20.	0.3	1
533	Question-based Drug Development for psilocybin – Authors' reply. Lancet Psychiatry,the, 2016, 3, 807.	7.4	1
534	New ACMD regulations threaten UK's pharmaceutical discovery. Lancet, The, 2017, 389, 2283.	13.7	1
535	The development and validation of a human screening model of tobacco abstinence. Drug and Alcohol Dependence, 2020, 206, 107720.	3.2	1
536	Drugs to Treat Attention Deficit Hyperactivity Disorder (ADHD). , 2020, , 392-432.		1
537	A Risky Business? Comparing the Harms of Alcohol and Other Recreational Drugs. Significance, 2021, 18, 40-42.	0.4	1
538	Some Contributions on How to Formulate Drug Policies and Provide Evidence-Based Regulation. American Journal of Bioethics, 2021, 21, 28-31.	0.9	1
539	Putting the MD back into MDMA. Nature Medicine, 2021, 27, 950-951.	30.7	1
540	More than just smoke: Psychopharmacology of cannabinoids. Journal of Psychopharmacology, 2021, 35, 771-772.	4.0	1

#	Article	IF	CITATIONS
541	The Neurochemistry of Addiction. Human Psychopharmacology, 1997, 12, S53-S58.	1.5	1
542	The Tryptophan Depletion Technique in Psychiatric Research. , 0, , 359-369.		1
543	Regulating the oxides of nitrogen – popping the myths. Drug Science, Policy and Law, 2022, 8, 205032452210852.	1.3	1
544	Current Trends in Cognitive Behaviour Therapy for Anxiety Disorders. , 0, , 265-286.		0
545	Post-Traumatic Syndromes: Comparative Biology and Psychology. , 0, , 205-221.		0
546	Obsessive-Compulsive Disorder: Diagnostic Considerations and an Epidemiological Update. , 0, , 157-168.		0
547	Genetics of Anxiety Disorders: Part I. , 0, , 25-40.		0
548	Genetics of Anxiety Disorders: Part II. , 0, , 41-50.		0
549	Obsessive-Compulsive Disorder: Biology and Treatment, a Generation of Progress. , 0, , 169-186.		0
550	Specific Phobias. , 0, , 105-135.		0
551	Social Phobia. , 0, , 137-155.		0
552	Drugs of AbuseJohn Q. WangHumana Press. ISBN: 1â€588â€29057â€3, 2003, 505 pp. with index, \$135.00. J Substance Use, 2003, 8, 279-279.	Journal of	0
553	Introducing the Pharmacology Behind Treatments to Understand Treatment Challenges. European Psychiatry, 2009, 24, .	0.2	0
554	Author's reply: â€~Suppressing addiction using high-dose baclofen, rather than using substitution therapy'. Journal of Psychopharmacology, 2012, 26, 1044-1044.	4.0	0
555	Neuropsychopharmacology across brain diseases. European Neuropsychopharmacology, 2012, 22, 844-846.	0.7	0
556	Assessment of the quality of brain regions and neuroimaging metrics as biomarkers of Alzheimer's Disease. EJNMMI Physics, 2015, 2, A46.	2.7	0
557	Thirty years of <i>Journal of Psychopharmacology</i> . Journal of Psychopharmacology, 2016, 30, 1071-1071.	4.0	0
558	19th biennial IPEG Meeting. Neuropsychiatric Electrophysiology, 2016, 2, .	4.1	0

0

#	Article	IF	Citations
559	A multicenter positron emission tomography study of GABA receptor availability in adults with autism. European Neuropsychopharmacology, 2017, 27, S716-S717.	0.7	0
560	A Brief History of Psychopharmacology. , 2020, , 1-34.		0
561	Neurotransmission and Mechanisms of Drug Action. , 2020, , 69-123.		0
562	Pharmacodynamics and Pharmacokinetics. , 2020, , 124-150.		0
563	Good Clinical Practice in Psychopharmacology. , 2020, , 203-203.		0
564	Drugs to Treat Depression. , 2020, , 227-267.		0
565	Drugs to Treat Anxiety and Insomnia. , 2020, , 268-289.		Ο
566	Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than) Tj ETQq0 C	0 rgBT /C	Overlock 10 Th
567	Anticonvulsants for Mental Disorders: Valproate, Lamotrigine, Carbamazepine and Oxcarbazepine. , 2020, , 362-391.		0
568	Drugs to Treat Dementia. , 2020, , 433-453.		0
569	Drugs to Treat Substance Use Disorders. , 2020, , 454-494.		Ο
570	Electroconvulsive Therapy and Neuromodulation Therapies. , 2020, , 495-495.		0
571	Psychotropic Drug Treatment in Childhood and Adolescence. , 2020, , 525-542.		0
572	Psychotropic Drug Treatment in Later Life. , 2020, , 543-576.		0

Psychotropic Prescribing in Pregnancy and Lactation. , 2020, , 577-598.

574 The Clinical Management of Acute Disturbance Including Rapid Tranquillisation. , 2020, , 599-618.

575	Antipsychotics, Weight Gain and Metabolic Risk. , 2020, , 619-619.		0	
576	<B>Dopamine and social anxiety disorder</B> . Revista Brasileira De Psiquiatria, 2006, 28, .	1.7	0	

#	Article	IF	CITATIONS
577	Psychopharmacology: An Introduction (3rd edn). By René Spiegel. Chichester: John Wiley. 1996. 295 pp. £45 (hb). ISBN: 0 471 95729 1. British Journal of Psychiatry, 1997, 170, 96-96.	2.8	0
578	Practical pharmacotherapy for anxiety disorders. Advances in Psychiatric Treatment, 1997, 3, 65-65.	0.5	0
579	The psychopharmacology of anxiety. British Journal of Hospital Medicine, 1996, 55, 187-91.	0.0	0